International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-1 doi: 10.5281/zenodo.10608724
Case Report
DRESS Syndrome – A Case Report with Learning Points
 ,
 ,
Published
Jan. 31, 2024
Abstract

Background: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a critical drug-induced hypersensitivity, often associated with antiepileptic drugs.

Case Report: A 21-year-old male with epilepsy developed DRESS syndrome after 8 weeks of phenytoin treatment. Symptoms included fever, widespread erythematous rashes, lymphadenopathy, and gastrointestinal discomfort. Laboratory findings showed leukocytosis, eosinophilia, and elevated liver enzymes, with high serum phenytoin levels. The Regi SCAR score was 7, confirming the diagnosis. Management involved discontinuing phenytoin, starting alternative antiepileptics, and administering corticosteroids and immunosuppressants, leading to patient improvement.

Discussion: This case emphasizes the necessity of early recognition and management of DRESS syndrome in patients on antiepileptic medication. It highlights the importance of the RegiSCAR criteria for diagnosis and the need for vigilant drug level monitoring. The variable presentation of DRESS syndrome, often leading to misdiagnosis, is also discussed.

Conclusion: DRESS syndrome is a life-threatening condition requiring prompt diagnosis and treatment. Awareness among clinicians is essential for early intervention and improved patient outcomes

Recommended Articles
Loading Image...
Volume-5, Issue-1
Citations
2579 Views
288 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved